Industry Research Reports
Home > Reports > Chemical & Material > Global Nicotinamide Mononucleotide (NMN) Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Nicotinamide Mononucleotide (NMN) Market Outlook, In‑Depth Analysis & Forecast to 2032
Industry: Chemical & Material
Published Date: 2026-08-01
Pages: 156 Pages
Report ld: 5614596
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Nicotinamide Mononucleotide (NMN) Market Size(US$)
CAGR 2026-2032
9.2%
Market Size,2032
USD 382
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 226 million
Market Forecast in 2032(Value)
US$ 382 million
CAGR
9.2%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Nicotinamide Mononucleotide (NMN) market is projected to grow from US$ 190 million in 2025 to US$ 382 million by 2032, at a CAGR of 9.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
In 2025, global sales volume of Nicotinamide Mononucleotide (NMN) reached 397.8 metric tons, with an average price of $478 per kilogram.
Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis produced from nicotinamide through nicotinamide phosphoribosyltransferase (NAMPT) and also referred to as NMN or nicotinamide ribotide. In recent studies of NMN applications to prevention and diagnosis of age-dependent diseases such as diabetes, neurodegenerative disorder, cardiac disease etc., it has become one of hottest biomarkers on discussion for anti-aging, lately.
NMN is a precursor of nicotinamide adenine dinucleotide (NAD+), which plays a vital role in cell metabolism and energy production. As we age, the level of NAD+ in the human body gradually decreases, resulting in weakened cell metabolism, which in turn triggers a series of aging-related diseases. Therefore, increasing the level of NAD+ in the body by supplementing NMN has become a new way to fight aging and maintain good health.
With the general improvement of global health awareness and continuous breakthroughs in scientific research and technology, the growth momentum of the NMN market will continue to increase. In the future, the NMN market will achieve a deeper cross-border integration with other health industries such as biotechnology, precision medicine, and nutritional supplements, giving rise to a series of innovative products and service models to meet consumers' more personalized and precise health needs.
At present, nicotinamide mononucleotide (NMN) is still in the development stage. There are not many manufacturers in the global market, and consumers have weak awareness of its use, especially in developing countries. The demand is lower than that in developed countries around the world, but the demand in developing countries is growing rapidly. Leading giants have proposed expansion plans and increased production bases.
Nicotinamide mononucleotide (NMN) core manufacturers include GeneHarbor, Mirailab Bioscience, Maac10 Formulas, Herbalmax and Genex Formula. China is the largest production area, accounting for about 84% of the global market share, followed by North America and Japan. The downstream applications of nicotinamide mononucleotide include health products, cosmetics, etc. Globally, health products are the largest application market, and raw materials for health products account for 82% of the total sales of nicotinamide mononucleotide in 2025.
MARKET SEGMENTATION
By Company
- GeneHarbor (HK)
- Herbalmax (US)
- Genex Formulas (US)
- Mirailab Bioscience (JP)
- Maac10 Formulas (US)
- EffePharm (CN)
- Bontac (CN)
- CELFULL (US)
- Kingdomway (CN)
- ABA Chemical (CN)
- SyncoZymes (CN)
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Content ≥98%
- Content ＜98%
Segment by Application
- Health Care Products
- Cosmetics
- Others
Segment by Category
- Enzymatic Catalysis
- Microbial Fermentation
- Chemical Synthesis
- Other
Segment by Division
- Food Grade
- Cosmetic Grade
- Pharmaceutical Grade
REPORT SCOPE
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Nicotinamide Mononucleotide (NMN) market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (capacity, sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
CHAPTER OUTLINE
Chapter 1: Defines the Nicotinamide Mononucleotide (NMN) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue, sales, and production to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: Maps global production capacity, utilization, and market share (2021–2032), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks
Chapter 7: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 8: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 9: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 10: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 11: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth: details product specs, capacity, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 13: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles
Chapter 14: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 7-11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Nicotinamide Mononucleotide (NMN): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Nicotinamide Mononucleotide (NMN) Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Content ≥98%
1.2.3 Content ＜98%
1.3 Market Segmentation by Production Process
1.3.1 Global Nicotinamide Mononucleotide (NMN) Market Size by Production Process, 2021 vs 2025 vs 2032
1.3.2 Enzymatic Catalysis
1.3.3 Microbial Fermentation
1.3.4 Chemical Synthesis
1.3.5 Other
1.4 Market Segmentation by Grade
1.4.1 Global Nicotinamide Mononucleotide (NMN) Market Size by Grade, 2021 vs 2025 vs 2032
1.4.2 Food Grade
1.4.3 Cosmetic Grade
1.4.4 Pharmaceutical Grade
1.5 Market Segmentation by Application
1.5.1 Global Nicotinamide Mononucleotide (NMN) Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Health Care Products
1.5.3 Cosmetics
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Nicotinamide Mononucleotide (NMN) Revenue Estimates and Forecasts (2021-2032)
2.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Nicotinamide Mononucleotide (NMN) Sales Estimates and Forecasts (2021-2032)
2.4 Global Nicotinamide Mononucleotide (NMN) Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Global Sales Market Share by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.5 Global Nicotinamide Mononucleotide (NMN) Production Capacity and Utilization (2021 vs 2025 vs 2032)
2.6 Production Comparison by Region: 2021 vs 2025 vs 2032
3 Competitive Landscape
3.1 Global Nicotinamide Mononucleotide (NMN) Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Nicotinamide Mononucleotide (NMN) Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs. 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Content ≥98%: Market Share by Key Manufacturers
3.5.2 Content ＜98%: Market Share by Key Manufacturers
3.6 Global Nicotinamide Mononucleotide (NMN) Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Market Entry and Exit Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Product Segmentation
4.1 Global Nicotinamide Mononucleotide (NMN) Sales Performance by Type
4.1.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type (2021-2032)
4.1.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Nicotinamide Mononucleotide (NMN) Sales Performance by Production Process
4.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Production Process (2021-2032)
4.2.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Production Process (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Production Process (2021-2032)
4.3 Global Nicotinamide Mononucleotide (NMN) Sales Performance by Grade
4.3.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Grade (2021-2032)
4.3.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Grade (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Grade (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Nicotinamide Mononucleotide (NMN) Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 Global Production Analysis
6.1 Global Nicotinamide Mononucleotide (NMN) Production Capacity and Utilization Rates (2021–2032)
6.2 Regional Production Dynamics and Outlook
6.2.1 Historic Production by Region (2021-2026)
6.2.2 Forecasted Production by Region (2027-2032)
6.2.3 Production Market Share by Region (2021-2032)
6.2.4 Regulatory and Trade Policy Impact on Production
6.2.5 Production Capacity Enablers and Constraints
6.3 Key Regional Production Hubs
6.3.1 North America
6.3.2 China
6.3.3 Japan
7 North America
7.1 North America Sales Volume and Revenue (2021-2032)
7.2 North America Key Manufacturers Sales Revenue in 2025
7.3 North America Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2021-2032)
7.4 North America Growth Accelerators and Market Barriers
7.5 North America Nicotinamide Mononucleotide (NMN) Market Size by Country
7.5.1 North America Revenue by Country
7.5.2 North America Sales Trends by Country
7.5.3 US
7.5.4 Canada
7.5.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2021-2032)
8.2 Europe Key Manufacturers Sales Revenue in 2025
8.3 Europe Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2021-2032)
8.4 Europe Growth Accelerators and Market Barriers
8.5 Europe Nicotinamide Mononucleotide (NMN) Market Size by Country
8.5.1 Europe Revenue by Country
8.5.2 Europe Sales Trends by Country
8.5.3 Germany
8.5.4 France
8.5.5 U.K.
8.5.6 Italy
8.5.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
9.3 Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2021-2032)
9.4 Asia-Pacific Nicotinamide Mononucleotide (NMN) Market Size by Region
9.4.1 Asia-Pacific Revenue by Region
9.4.2 Asia-Pacific Sales Trends by Region
9.5 Asia-Pacific Growth Accelerators and Market Barriers
9.6 Southeast Asia
9.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
9.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.7 China
9.8 Japan
9.9 South Korea
9.10 China Taiwan
9.11 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2021-2032)
10.2 Central and South America Key Manufacturers Sales Revenue in 2025
10.3 Central and South America Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2021-2032)
10.4 Central and South America Investment Opportunities and Key Challenges
10.5 Central and South America Nicotinamide Mononucleotide (NMN) Market Size by Country
10.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 Brazil
10.5.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
11.3 Middle East and Africa Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2021-2032)
11.4 Middle East and Africa Investment Opportunities and Key Challenges
11.5 Middle East and Africa Nicotinamide Mononucleotide (NMN) Market Size by Country
11.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
11.5.2 GCC Countries
11.5.3 Turkey
11.5.4 Egypt
11.5.5 South Africa
12 Corporate Profile
12.1 GeneHarbor (HK)
12.1.1 GeneHarbor (HK) Corporation Information
12.1.2 GeneHarbor (HK) Business Overview
12.1.3 GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.1.4 GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.1.5 GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) Sales by Product in 2025
12.1.6 GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) Sales by Application in 2025
12.1.7 GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2025
12.1.8 GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.1.9 GeneHarbor (HK) Recent Developments
12.2 Herbalmax (US)
12.2.1 Herbalmax (US) Corporation Information
12.2.2 Herbalmax (US) Business Overview
12.2.3 Herbalmax (US) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.2.4 Herbalmax (US) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.2.5 Herbalmax (US) Nicotinamide Mononucleotide (NMN) Sales by Product in 2025
12.2.6 Herbalmax (US) Nicotinamide Mononucleotide (NMN) Sales by Application in 2025
12.2.7 Herbalmax (US) Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2025
12.2.8 Herbalmax (US) Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.2.9 Herbalmax (US) Recent Developments
12.3 Genex Formulas (US)
12.3.1 Genex Formulas (US) Corporation Information
12.3.2 Genex Formulas (US) Business Overview
12.3.3 Genex Formulas (US) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.3.4 Genex Formulas (US) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.3.5 Genex Formulas (US) Nicotinamide Mononucleotide (NMN) Sales by Product in 2025
12.3.6 Genex Formulas (US) Nicotinamide Mononucleotide (NMN) Sales by Application in 2025
12.3.7 Genex Formulas (US) Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2025
12.3.8 Genex Formulas (US) Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.3.9 Genex Formulas (US) Recent Developments
12.4 Mirailab Bioscience (JP)
12.4.1 Mirailab Bioscience (JP) Corporation Information
12.4.2 Mirailab Bioscience (JP) Business Overview
12.4.3 Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.4.4 Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.4.5 Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) Sales by Product in 2025
12.4.6 Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) Sales by Application in 2025
12.4.7 Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2025
12.4.8 Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.4.9 Mirailab Bioscience (JP) Recent Developments
12.5 Maac10 Formulas (US)
12.5.1 Maac10 Formulas (US) Corporation Information
12.5.2 Maac10 Formulas (US) Business Overview
12.5.3 Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.5.4 Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.5.5 Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) Sales by Product in 2025
12.5.6 Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) Sales by Application in 2025
12.5.7 Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2025
12.5.8 Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.5.9 Maac10 Formulas (US) Recent Developments
12.6 EffePharm (CN)
12.6.1 EffePharm (CN) Corporation Information
12.6.2 EffePharm (CN) Business Overview
12.6.3 EffePharm (CN) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.6.4 EffePharm (CN) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.6.5 EffePharm (CN) Recent Developments
12.7 Bontac (CN)
12.7.1 Bontac (CN) Corporation Information
12.7.2 Bontac (CN) Business Overview
12.7.3 Bontac (CN) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.7.4 Bontac (CN) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.7.5 Bontac (CN) Recent Developments
12.8 CELFULL (US)
12.8.1 CELFULL (US) Corporation Information
12.8.2 CELFULL (US) Business Overview
12.8.3 CELFULL (US) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.8.4 CELFULL (US) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.8.5 CELFULL (US) Recent Developments
12.9 Kingdomway (CN)
12.9.1 Kingdomway (CN) Corporation Information
12.9.2 Kingdomway (CN) Business Overview
12.9.3 Kingdomway (CN) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.9.4 Kingdomway (CN) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.9.5 Kingdomway (CN) Recent Developments
12.10 ABA Chemical (CN)
12.10.1 ABA Chemical (CN) Corporation Information
12.10.2 ABA Chemical (CN) Business Overview
12.10.3 ABA Chemical (CN) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.10.4 ABA Chemical (CN) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.10.5 ABA Chemical (CN) Recent Developments
12.11 SyncoZymes (CN)
12.11.1 SyncoZymes (CN) Corporation Information
12.11.2 SyncoZymes (CN) Business Overview
12.11.3 SyncoZymes (CN) Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.11.4 SyncoZymes (CN) Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2021-2026)
12.11.5 SyncoZymes (CN) Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Nicotinamide Mononucleotide (NMN) Industry Chain
13.2 Nicotinamide Mononucleotide (NMN) Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Nicotinamide Mononucleotide (NMN) Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Nicotinamide Mononucleotide (NMN) Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Nicotinamide Mononucleotide (NMN) Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
14.4 Impact of U.S. Tariffs
15 Key Findings in the Global Nicotinamide Mononucleotide (NMN) Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Production Process, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Grade, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Nicotinamide Mononucleotide (NMN) Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (Tons)
Table 7. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 8. Global Nicotinamide Mononucleotide (NMN) Production Growth Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (Tons)
Table 9. Global Nicotinamide Mononucleotide (NMN) Sales by Manufacturers (Tons), 2021-2026
Table 10. Global Nicotinamide Mononucleotide (NMN) Sales Share by Manufacturers (2021-2026)
Table 11. Global Nicotinamide Mononucleotide (NMN) Revenue by Manufacturers (US$ Million), 2021-2026
Table 12. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share by Manufacturers (2021-2026)
Table 13. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 14. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Nicotinamide Mononucleotide (NMN) Revenue, 2025
Table 15. Global Nicotinamide Mononucleotide (NMN) Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 16. Global Nicotinamide Mononucleotide (NMN) Average Selling Price (ASP) by Manufacturers (US$/Kg), 2021-2026
Table 17. Key Manufacturers Nicotinamide Mononucleotide (NMN) Manufacturing Base and Headquarters
Table 18. Global Nicotinamide Mononucleotide (NMN) Market Concentration Ratio (CR5)
Table 19. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 20. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 21. Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type (Tons), 2021-2026
Table 22. Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type (Tons), 2027-2032
Table 23. Global Nicotinamide Mononucleotide (NMN) Revenue by Type (US$ Million), 2021-2026
Table 24. Global Nicotinamide Mononucleotide (NMN) Revenue by Type (US$ Million), 2027-2032
Table 25. Global Nicotinamide Mononucleotide (NMN) Sales Volume by Production Process (Tons), 2021-2026
Table 26. Global Nicotinamide Mononucleotide (NMN) Sales Volume by Production Process (Tons), 2027-2032
Table 27. Global Nicotinamide Mononucleotide (NMN) Revenue by Production Process (US$ Million), 2021-2026
Table 28. Global Nicotinamide Mononucleotide (NMN) Revenue by Production Process (US$ Million), 2027-2032
Table 29. Global Nicotinamide Mononucleotide (NMN) Sales Volume by Grade (Tons), 2021-2026
Table 30. Global Nicotinamide Mononucleotide (NMN) Sales Volume by Grade (Tons), 2027-2032
Table 31. Global Nicotinamide Mononucleotide (NMN) Revenue by Grade (US$ Million), 2021-2026
Table 32. Global Nicotinamide Mononucleotide (NMN) Revenue by Grade (US$ Million), 2027-2032
Table 33. Technical Specifications by Key Product Type
Table 34. Global Nicotinamide Mononucleotide (NMN) Sales by Application (Tons), 2021-2026
Table 35. Global Nicotinamide Mononucleotide (NMN) Sales by Application (Tons), 2027-2032
Table 36. Nicotinamide Mononucleotide (NMN) High-Growth Sectors Demand CAGR (2026-2032)
Table 37. Global Nicotinamide Mononucleotide (NMN) Revenue by Application (US$ Million), 2021-2026
Table 38. Global Nicotinamide Mononucleotide (NMN) Revenue by Application (US$ Million), 2027-2032
Table 39. Top Customers by Region
Table 40. Top Customers by Application
Table 41. Global Nicotinamide Mononucleotide (NMN) Production by Region (Tons), 2021-2026
Table 42. Global Nicotinamide Mononucleotide (NMN) Production by Region (Tons), 2027-2032
Table 43. North America Nicotinamide Mononucleotide (NMN) Growth Accelerators and Market Barriers
Table 44. North America Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 45. North America Nicotinamide Mononucleotide (NMN) Sales (Tons) by Country (2021 vs 2025 vs 2032)
Table 46. Europe Nicotinamide Mononucleotide (NMN) Growth Accelerators and Market Barriers
Table 47. Europe Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Europe Nicotinamide Mononucleotide (NMN) Sales (Tons) by Country (2021 vs 2025 vs 2032)
Table 49. Asia-Pacific Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 50. Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales (Tons) by Country (2021 vs 2025 vs 2032)
Table 51. Asia-Pacific Nicotinamide Mononucleotide (NMN) Growth Accelerators and Market Barriers
Table 52. Southeast Asia Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 53. Central and South America Nicotinamide Mononucleotide (NMN) Investment Opportunities and Key Challenges
Table 54. Central and South America Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 55. Middle East and Africa Nicotinamide Mononucleotide (NMN) Investment Opportunities and Key Challenges
Table 56. Middle East and Africa Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 57. GeneHarbor (HK) Corporation Information
Table 58. GeneHarbor (HK) Description and Major Businesses
Table 59. GeneHarbor (HK) Product Models, Descriptions and Specifications
Table 60. GeneHarbor (HK) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 61. GeneHarbor (HK) Sales Value Proportion by Product in 2025
Table 62. GeneHarbor (HK) Sales Value Proportion by Application in 2025
Table 63. GeneHarbor (HK) Sales Value Proportion by Geographic Area in 2025
Table 64. GeneHarbor (HK) Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 65. GeneHarbor (HK) Recent Developments
Table 66. Herbalmax (US) Corporation Information
Table 67. Herbalmax (US) Description and Major Businesses
Table 68. Herbalmax (US) Product Models, Descriptions and Specifications
Table 69. Herbalmax (US) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 70. Herbalmax (US) Sales Value Proportion by Product in 2025
Table 71. Herbalmax (US) Sales Value Proportion by Application in 2025
Table 72. Herbalmax (US) Sales Value Proportion by Geographic Area in 2025
Table 73. Herbalmax (US) Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 74. Herbalmax (US) Recent Developments
Table 75. Genex Formulas (US) Corporation Information
Table 76. Genex Formulas (US) Description and Major Businesses
Table 77. Genex Formulas (US) Product Models, Descriptions and Specifications
Table 78. Genex Formulas (US) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 79. Genex Formulas (US) Sales Value Proportion by Product in 2025
Table 80. Genex Formulas (US) Sales Value Proportion by Application in 2025
Table 81. Genex Formulas (US) Sales Value Proportion by Geographic Area in 2025
Table 82. Genex Formulas (US) Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 83. Genex Formulas (US) Recent Developments
Table 84. Mirailab Bioscience (JP) Corporation Information
Table 85. Mirailab Bioscience (JP) Description and Major Businesses
Table 86. Mirailab Bioscience (JP) Product Models, Descriptions and Specifications
Table 87. Mirailab Bioscience (JP) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 88. Mirailab Bioscience (JP) Sales Value Proportion by Product in 2025
Table 89. Mirailab Bioscience (JP) Sales Value Proportion by Application in 2025
Table 90. Mirailab Bioscience (JP) Sales Value Proportion by Geographic Area in 2025
Table 91. Mirailab Bioscience (JP) Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 92. Mirailab Bioscience (JP) Recent Developments
Table 93. Maac10 Formulas (US) Corporation Information
Table 94. Maac10 Formulas (US) Description and Major Businesses
Table 95. Maac10 Formulas (US) Product Models, Descriptions and Specifications
Table 96. Maac10 Formulas (US) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 97. Maac10 Formulas (US) Sales Value Proportion by Product in 2025
Table 98. Maac10 Formulas (US) Sales Value Proportion by Application in 2025
Table 99. Maac10 Formulas (US) Sales Value Proportion by Geographic Area in 2025
Table 100. Maac10 Formulas (US) Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 101. Maac10 Formulas (US) Recent Developments
Table 102. EffePharm (CN) Corporation Information
Table 103. EffePharm (CN) Description and Major Businesses
Table 104. EffePharm (CN) Product Models, Descriptions and Specifications
Table 105. EffePharm (CN) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 106. EffePharm (CN) Recent Developments
Table 107. Bontac (CN) Corporation Information
Table 108. Bontac (CN) Description and Major Businesses
Table 109. Bontac (CN) Product Models, Descriptions and Specifications
Table 110. Bontac (CN) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 111. Bontac (CN) Recent Developments
Table 112. CELFULL (US) Corporation Information
Table 113. CELFULL (US) Description and Major Businesses
Table 114. CELFULL (US) Product Models, Descriptions and Specifications
Table 115. CELFULL (US) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 116. CELFULL (US) Recent Developments
Table 117. Kingdomway (CN) Corporation Information
Table 118. Kingdomway (CN) Description and Major Businesses
Table 119. Kingdomway (CN) Product Models, Descriptions and Specifications
Table 120. Kingdomway (CN) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 121. Kingdomway (CN) Recent Developments
Table 122. ABA Chemical (CN) Corporation Information
Table 123. ABA Chemical (CN) Description and Major Businesses
Table 124. ABA Chemical (CN) Product Models, Descriptions and Specifications
Table 125. ABA Chemical (CN) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 126. ABA Chemical (CN) Recent Developments
Table 127. SyncoZymes (CN) Corporation Information
Table 128. SyncoZymes (CN) Description and Major Businesses
Table 129. SyncoZymes (CN) Product Models, Descriptions and Specifications
Table 130. SyncoZymes (CN) Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 131. SyncoZymes (CN) Recent Developments
Table 132. Key Raw Materials Distribution
Table 133. Raw Materials Key Suppliers
Table 134. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 135. Milestones in Production Technology Evolution
Table 136. Distributors List
Table 137. Market Trends and Market Evolution
Table 138. Market Drivers and Opportunities
Table 139. Market Challenges, Risks, and Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Nicotinamide Mononucleotide (NMN) Product Picture
Figure 2. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Content ≥98% Product Picture
Figure 4. Content ＜98% Product Picture
Figure 5. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Production Process, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Enzymatic Catalysis Product Picture
Figure 7. Microbial Fermentation Product Picture
Figure 8. Chemical Synthesis Product Picture
Figure 9. Other Product Picture
Figure 10. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Grade, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Food Grade Product Picture
Figure 12. Cosmetic Grade Product Picture
Figure 13. Pharmaceutical Grade Product Picture
Figure 14. Global Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Health Care Products
Figure 16. Cosmetics
Figure 17. Others
Figure 18. Nicotinamide Mononucleotide (NMN) Report Years Considered
Figure 19. Global Nicotinamide Mononucleotide (NMN) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 21. Global Nicotinamide Mononucleotide (NMN) Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Nicotinamide Mononucleotide (NMN) Sales (Tons), 2021-2032
Figure 24. Global Nicotinamide Mononucleotide (NMN) Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (Tons)
Figure 25. Global Nicotinamide Mononucleotide (NMN) Sales Market Share by Region (2021-2032)
Figure 26. Global Nicotinamide Mononucleotide (NMN) Capacity, Production and Utilization (Tons), 2021 vs 2025 vs 2032
Figure 27. Top 5 and Top 10 Manufacturers Nicotinamide Mononucleotide (NMN) Sales Volume Market Share in 2025
Figure 28. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share Ranking (2025)
Figure 29. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 30. Content ≥98% Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Content ＜98% Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Global Nicotinamide Mononucleotide (NMN) Sales Volume-Based Market Share by Type (2021-2032)
Figure 33. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share by Type (2021-2032)
Figure 34. Global Nicotinamide Mononucleotide (NMN) ASP by Type (US$/Kg), 2021-2032
Figure 35. Global Nicotinamide Mononucleotide (NMN) Sales Volume-Based Market Share by Production Process (2021-2032)
Figure 36. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share by Production Process (2021-2032)
Figure 37. Global Nicotinamide Mononucleotide (NMN) ASP by Production Process (US$/Kg), 2021-2032
Figure 38. Global Nicotinamide Mononucleotide (NMN) Sales Volume-Based Market Share by Grade (2021-2032)
Figure 39. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share by Grade (2021-2032)
Figure 40. Global Nicotinamide Mononucleotide (NMN) ASP by Grade (US$/Kg), 2021-2032
Figure 41. Global Nicotinamide Mononucleotide (NMN) Sales Market Share by Application (2021-2032)
Figure 42. Global Nicotinamide Mononucleotide (NMN) Revenue-Based Market Share by Application (2021-2032)
Figure 43. Global Nicotinamide Mononucleotide (NMN) ASP by Application (US$/Kg), 2021-2032
Figure 44. Global Nicotinamide Mononucleotide (NMN) Capacity, Production and Utilization (Tons), 2021-2032
Figure 45. Global Nicotinamide Mononucleotide (NMN) Production Market Share by Region (2021-2032)
Figure 46. Production Capacity Enablers & Constraints
Figure 47. Nicotinamide Mononucleotide (NMN) Production Growth Rate in North America (Tons), 2021-2032
Figure 48. Nicotinamide Mononucleotide (NMN) Production Growth Rate in China (Tons), 2021-2032
Figure 49. Nicotinamide Mononucleotide (NMN) Production Growth Rate in Japan (Tons), 2021-2032
Figure 50. North America Nicotinamide Mononucleotide (NMN) Sales YoY (Tons), 2021-2032
Figure 51. North America Nicotinamide Mononucleotide (NMN) Revenue YoY (US$ Million), 2021-2032
Figure 52. North America Top 5 Manufacturers Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2025
Figure 53. North America Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2021-2032)
Figure 54. North America Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2021-2032)
Figure 55. US Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 56. Canada Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 57. Mexico Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 58. Europe Nicotinamide Mononucleotide (NMN) Sales YoY (Tons), 2021-2032
Figure 59. Europe Nicotinamide Mononucleotide (NMN) Revenue YoY (US$ Million), 2021-2032
Figure 60. Europe Top 5 Manufacturers Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2025
Figure 61. Europe Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2021-2032)
Figure 62. Europe Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2021-2032)
Figure 63. Germany Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 64. France Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 65. U.K. Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 66. Italy Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 67. Russia Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 68. Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales YoY (Tons), 2021-2032
Figure 69. Asia-Pacific Nicotinamide Mononucleotide (NMN) Revenue YoY (US$ Million), 2021-2032
Figure 70. Asia-Pacific Top 8 Manufacturers Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2025
Figure 71. Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2021-2032)
Figure 72. Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2021-2032)
Figure 73. Indonesia Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 74. Japan Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 75. South Korea Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 76. China Taiwan Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 77. India Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 78. Central and South America Nicotinamide Mononucleotide (NMN) Sales YoY (Tons), 2021-2032
Figure 79. Central and South America Nicotinamide Mononucleotide (NMN) Revenue YoY (US$ Million), 2021-2032
Figure 80. Central and South America Top 5 Manufacturers Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2025
Figure 81. Central and South America Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2021-2032)
Figure 82. Central and South America Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2021-2032)
Figure 83. Brazil Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 84. Argentina Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 85. Middle East, and Africa Nicotinamide Mononucleotide (NMN) Sales YoY (Tons), 2021-2032
Figure 86. Middle East and Africa Nicotinamide Mononucleotide (NMN) Revenue YoY (US$ Million), 2021-2032
Figure 87. Middle East and Africa Top 5 Manufacturers Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2025
Figure 88. Middle East and Africa Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2021-2032)
Figure 89. Middle East and Africa Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2021-2032)
Figure 90. GCC Countries Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 91. Turkey Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 92. Egypt Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 93. South Africa Nicotinamide Mononucleotide (NMN) Revenue (US$ Million), 2021-2032
Figure 94. Nicotinamide Mononucleotide (NMN) Industry Chain Mapping
Figure 95. Regional Nicotinamide Mononucleotide (NMN) Manufacturing Base Distribution (%)
Figure 96. Nicotinamide Mononucleotide (NMN) Production Process
Figure 97. Regional Nicotinamide Mononucleotide (NMN) Production Cost Structure
Figure 98. Channels of Distribution (Direct Vs Distribution)
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Nicotinamide Mononucleotide (NMN) market?
The top companies in the global Nicotinamide Mononucleotide (NMN) market are GeneHarbor (HK)、Herbalmax (US)、Genex Formulas (US).
What is the annual compound growth rate of the global Nicotinamide Mononucleotide (NMN) market size from 2026 to 2032?
What was the global market size of Nicotinamide Mononucleotide (NMN) in 2032?
Which region is expected to have the highest market share?
What was the global market size of Nicotinamide Mononucleotide (NMN) in 2026?
Related Reports
Global Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Nicotinamide Mononucleotide (NMN) market size was US$ 190 million in 2025 and is forecast to reach a readjusted size of US$ 382 million by 2032 with a CAGR of 9.2% during the forecast period 2026-2032.
Published Date: 2026-08-01
Pages: 140
USD 4250.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Market Research Report 2026
The global Nicotinamide Mononucleotide (NMN) market was valued at US$ 190 million in 2025 and is anticipated to reach US$ 382 million by 2032, at a CAGR of 9.2% from 2026 to 2032.
Published Date: 2026-08-01
Pages: 144
USD 2900.00
(Single User License)
Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 190 million in 2025 and is projected to reach US$ 382 million, growing at a CAGR of 9.2% from 2026 to 2032.
Published Date: 2026-08-01
Pages: 137
USD 3950.00
(Single User License)
Nicotinamide Mononucleotide (NMN) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published Date: 2025-11-03
Pages: 110
USD 3950.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Nicotinamide Mononucleotide (NMN) market size was US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published Date: 2025-09-10
Pages: 78
USD 4250.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Nicotinamide Mononucleotide (NMN) market is projected to grow from US$ 418 million in 2024 to US$ 992 million by 2031, at a CAGR of 13.4% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-07-31
Pages: 144
USD 4900.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Market Insights, Forecast to 2031
The global Nicotinamide Mononucleotide (NMN) market is projected to grow from US$ 468 million in 2025 to US$ 992 million by 2031, at a Compound Annual Growth Rate (CAGR) of 13.4% during the forecast period.
Published Date: 2025-04-02
Pages: 141
USD 4900.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Market Research Report 2025
The global market for Nicotinamide Mononucleotide (NMN) was valued at US$ 418 million in the year 2024 and is projected to reach a revised size of US$ 992 million by 2031, growing at a CAGR of 13.4% during the forecast period.
Published Date: 2025-04-02
Pages: 89
USD 2900.00
(Single User License)
Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published Date: 2025-02-07
Pages: 109
USD 3950.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Market Insights, Forecast to 2030
Valued at US$ 418 million in 2024, the global Nicotinamide Mononucleotide (NMN) market is forecast to reach US$ 886 million by 2030, at a CAGR of 13.4% during the forecast period.
Published Date: 2024-12-20
Pages: 146
USD 4900.00
(Single User License)
Global Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Nicotinamide Mononucleotide (NMN) market size was US$ 190 million in 2025 and is forecast to reach a readjusted size of US$ 382 million by 2032 with a CAGR of 9.2% during the forecast period 2026-2032.
Published: 2026-08-01
Pages: 140
USD 4250.00 (Single User License)Global Nicotinamide Mononucleotide (NMN) Market Research Report 2026
The global Nicotinamide Mononucleotide (NMN) market was valued at US$ 190 million in 2025 and is anticipated to reach US$ 382 million by 2032, at a CAGR of 9.2% from 2026 to 2032.
Published: 2026-08-01
Pages: 144
USD 2900.00 (Single User License)Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 190 million in 2025 and is projected to reach US$ 382 million, growing at a CAGR of 9.2% from 2026 to 2032.
Published: 2026-08-01
Pages: 137
USD 3950.00 (Single User License)Nicotinamide Mononucleotide (NMN) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published: 2025-11-03
Pages: 110
USD 3950.00 (Single User License)Global Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Nicotinamide Mononucleotide (NMN) market size was US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published: 2025-09-10
Pages: 78
USD 4250.00 (Single User License)Global Nicotinamide Mononucleotide (NMN) Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Nicotinamide Mononucleotide (NMN) market is projected to grow from US$ 418 million in 2024 to US$ 992 million by 2031, at a CAGR of 13.4% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-07-31
Pages: 144
USD 4900.00 (Single User License)Global Nicotinamide Mononucleotide (NMN) Market Insights, Forecast to 2031
The global Nicotinamide Mononucleotide (NMN) market is projected to grow from US$ 468 million in 2025 to US$ 992 million by 2031, at a Compound Annual Growth Rate (CAGR) of 13.4% during the forecast period.
Published: 2025-04-02
Pages: 141
USD 4900.00 (Single User License)Global Nicotinamide Mononucleotide (NMN) Market Research Report 2025
The global market for Nicotinamide Mononucleotide (NMN) was valued at US$ 418 million in the year 2024 and is projected to reach a revised size of US$ 992 million by 2031, growing at a CAGR of 13.4% during the forecast period.
Published: 2025-04-02
Pages: 89
USD 2900.00 (Single User License)Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published: 2025-02-07
Pages: 109
USD 3950.00 (Single User License)Global Nicotinamide Mononucleotide (NMN) Market Insights, Forecast to 2030
Valued at US$ 418 million in 2024, the global Nicotinamide Mononucleotide (NMN) market is forecast to reach US$ 886 million by 2030, at a CAGR of 13.4% during the forecast period.
Published: 2024-12-20
Pages: 146
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now